Xuwen Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuwen Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adrian D. Vickers
RTI Health Solutions
1 shared publication - Ernest Nadal
Department of Medical Oncology, Institut Català d’Oncologia (ICO), IDIBELL, Bellvitge Healthcare Campus, L’Hospitalet de Llobregat, Barcelona, Spain
1 shared publication - Maximillian Johannes Hochmair
Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, 1210 Vienna, Austria
1 shared publication - Sorrel Wolowacz
RTI Health Solutions
1 shared publication - Tarun Puri
Eli Lilly and Company, Indianapolis, IN 46285, USA
1 shared publication - Urpo Kiiskinen
Eli Lilly and Company, Indianapolis, IN, USA
1 shared publication
Latest Publications
- Open Access
- 3 June 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (15) , 1867-1878
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer
Selpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer. Efficacy and safety were compared using matching-adjusted indirect comparison. Median progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively. Outcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade ≥ 3 TRAEs.
- 3 June 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (15) , 1867-1878
Open AccessMatching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer
Selpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer. Efficacy and safety were compared using matching-adjusted indirect comparison. Median progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively. Outcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade ≥ 3 TRAEs.